Ordering Recommendation

Assess risk for lupus nephritis and global systemic lupus erythematosus (SLE) disease activity.


Semi-Quantitative Enzyme-Linked Immunosorbent Assay




1-15 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation

Serum separator tube.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)

Storage/Transport Temperature


Unacceptable Conditions

Urine or plasma. Contaminated, heat-inactivated, severely hemolyzed or severely lipemic specimens.


After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Reference Interval

0-19 Units Negative
20-39 Units Equivocal
40 Units or greater Positive

Interpretive Data

The presence of the anti-C1q IgG antibody may be associated with increased risk of lupus nephritis or with systemic lupus erythematosus (SLE) global activity. Anti-C1q antibodies are not specific for SLE; strong clinical correlation with disease is recommended.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Analyte Specific Reagent (ASR)


Hotline History


CPT Codes



Component Test Code* Component Chart Name LOINC
2007602 Anti-C1q Antibody, IgG 44702-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • C1q IgG Ab
Anti-C1q Antibody, IgG